Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19632861 | 0.89 | AGPAT2 (0.39) | NAMPTHDAC8HDAC6MEN1KMT2A | |
| SCHEMBL20796305 | 0.88 | KMT2A (0.42) | NAMPTMEN1KMT2A | |
| SCHEMBL19636657 | 0.85 | DRD2 (0.38) | NAMPTHDAC1 | |
| Hydrochloric Acid SCHEMBL30944564 | 0.82 | MEN1 (0.41) | MEN1KMT2AAGPAT2KDM4E | |
| SCHEMBL19633019 | 0.78 | GRM4 (0.37) | NAMPTMEN1KMT2AAGPAT2KDM4E | |
| Hydrochloric Acid SCHEMBL30464353 | 0.77 | GRM4 (0.37) | NAMPTMEN1KMT2AAGPAT2KDM4E | |
| SCHEMBL19633222 | 0.77 | USP4 (0.39) | MEN1KMT2AKDM4E | |
| SCHEMBL19614875 | 0.77 | FGFR1 (0.39) | MEN1KMT2AAGPAT2ERBB2 | |
| Hydrochloric Acid SCHEMBL19614868 | 0.75 | ERBB2 (0.38) | AGPAT2KDM4EERBB2 | |
| Hydrochloric Acid SCHEMBL30464368 | 0.75 | ERBB2 (0.38) | AGPAT2KDM4EERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | NAMPT 3033/4885HDAC8 1370/4885HDAC6 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.